Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer – a multicenter trial of the „Arbeitsgemeinschaft Internistische Onkologie“ (AIO) - Boeck, H S; Vehling-Kaiser, U; Waldschmidt, D (Onkologie, 2010)
et al.